About DIANT Pharma

DIANT Pharma develops continuous processing technology using proprietary DIANT® Jet systems for the scalable production of lipid and polymer-based nanoparticles. This technology enhances the uniformity and quality of nanoparticle drug products and vaccines while reducing manufacturing risks and accelerating time to market.

```xml <problem> Traditional methods of nanoparticle production for drug delivery and vaccines often suffer from inconsistent particle size and quality, leading to manufacturing inefficiencies and increased risks in product development and scalability. Current batch processes lack the real-time control necessary to ensure uniformity and optimal yield. </problem> <solution> DIANT Pharma offers continuous processing technology leveraging its proprietary DIANT® Jet systems for the scalable manufacturing of lipid and polymer-based nanoparticles. The DIANT® Jet technology enhances nanoparticle uniformity and quality through streamlined control and integrated testing, leading to better medicines and nanoparticle products. Their DIANT® LARU and LiFT systems accelerate R&D, increase efficiency, and reduce cGMP manufacturing risk by enabling automatic inline control of nanoparticle size and characteristics. DIANT® Pharma also offers R&D services and turnkey modular solutions for nanoparticle production. </solution> <features> - DIANT® Jet technology for continuous nanoparticle manufacturing. - DIANT® LARU: Benchtop system for R&D and academic work. - DIANT® LiFT: Commercial system for continuous production of lipid and polymer-based nanoparticles. - Automatic inline control of nanoparticle size and characteristics. - Integrated testing for real-time quality control. - Turnkey modular solutions for nanoparticle production. </features> <target_audience> The primary customers are innovators and CDMOs in the pharmaceutical, vaccine, nutraceutical, food/beverage, and cosmetics industries seeking to improve nanoparticle production for drug delivery and other applications. </target_audience> ```

What does DIANT Pharma do?

Where is DIANT Pharma located?

DIANT Pharma is based in Ans, United States.

When was DIANT Pharma founded?

DIANT Pharma was founded in 2019.

How much funding has DIANT Pharma raised?

DIANT Pharma has raised 1400000.

Location

Ans, United States

Founded

2019

Funding

1400000

Employees

14 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

DIANT Pharma

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

diantpharma.com 700+

Crunchbase

Founded 2019 – Ans, United States

Funding

Estimated Funding

$1M+

Team (10+)

No team information available.

Company Description

Problem

Traditional methods of nanoparticle production for drug delivery and vaccines often suffer from inconsistent particle size and quality, leading to manufacturing inefficiencies and increased risks in product development and scalability. Current batch processes lack the real-time control necessary to ensure uniformity and optimal yield.

Solution

DIANT Pharma offers continuous processing technology leveraging its proprietary DIANT® Jet systems for the scalable manufacturing of lipid and polymer-based nanoparticles. The DIANT® Jet technology enhances nanoparticle uniformity and quality through streamlined control and integrated testing, leading to better medicines and nanoparticle products. Their DIANT® LARU and LiFT systems accelerate R&D, increase efficiency, and reduce cGMP manufacturing risk by enabling automatic inline control of nanoparticle size and characteristics. DIANT® Pharma also offers R&D services and turnkey modular solutions for nanoparticle production.

Features

DIANT® Jet technology for continuous nanoparticle manufacturing.

DIANT® LARU: Benchtop system for R&D and academic work.

DIANT® LiFT: Commercial system for continuous production of lipid and polymer-based nanoparticles.

Automatic inline control of nanoparticle size and characteristics.

Integrated testing for real-time quality control.

Turnkey modular solutions for nanoparticle production.

Target Audience

The primary customers are innovators and CDMOs in the pharmaceutical, vaccine, nutraceutical, food/beverage, and cosmetics industries seeking to improve nanoparticle production for drug delivery and other applications.